May 15, 2025
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
Mar 25, 2025
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Mar 24, 2025
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Mar 13, 2025
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Mar 04, 2025
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Feb 24, 2025
PAVmed and Subsidiary Veris Health Complete Private Placement Financing
Feb 20, 2025
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Nov 14, 2024
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
Oct 10, 2024
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
Sep 10, 2024
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
Aug 13, 2024
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
Aug 06, 2024
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Jul 30, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
Apr 30, 2024
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Mar 26, 2024
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results